Last reviewed · How we verify
NCT07143864
Efficacy and Safety of Stapokibart for Primary Cutaneous Amyloidosis
NA trial testing Stapokibart in Primary Cutaneous Amyloidosis in 40 participants. Not yet recruiting.
31 December 2026
Quick facts
| Lead sponsor | First Affiliated Hospital of Chongqing Medical University |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 15 September 2025 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
Drugs / interventions tested
- Stapokibart — full drug profile →
- Placebo drug — full drug profile →
Conditions studied
- Primary Cutaneous Amyloidosis — all drugs for Primary Cutaneous Amyloidosis →
Sponsor
First Affiliated Hospital of Chongqing Medical University
Who can join
Adults 18 to 75, any sex, with Primary Cutaneous Amyloidosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial is planned to investigate the efficacy and safety of Stapokibart (an IL-4 receptor antagonist) in patients with PCA.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07143864
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Stapokibart
Trials testing the same drug.
- NCT06801353 — A Cohort Study on Biomarkers to Predict the Efficacy of Biologics for Chronic Rhinosinusitis with Nasal Polyps · Phase 4 · not yet recruiting
- NCT06424470 — Study on the Treatment of Prurigo Nodularis With Stapokibart Injection · Phase 3 · active not recruiting
Other First Affiliated Hospital of Chongqing Medical University trials
Trials by the same sponsor.
- NCT07369713 — Efficacy and Safety of Accelerated Intermittent Theta-burst Stimulation (a-iTBS) in Adolescents With Depressive Disorder · NA · not yet recruiting
- NCT07499323 — Talquetamab in Patients With Refractory Generalized Myasthenia Gravis · NA · not yet recruiting
- NCT07409870 — An Integrated Multi-omics Study on the Molecular Mechanisms of Ureteral Stricture · not yet recruiting
- NCT07324473 — Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired R · Phase 2 · not yet recruiting
- NCT07203144 — Selenium Supplementation for Improving Depression in Children and Adolescents: Efficacy and Mechanistic Study · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07143864 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital of Chongqing Medical University
- Last refreshed: 27 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07143864.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing